Nasdaq apls.

14 дек. 2017 г. ... More from Nasdaq. 09:11. Abivax [ABVX] Rings the. Nasdaq Closing Bell. 1 day ago · 564 views. 00:34. As home to the world's most innovative and ...Apellis Pharmaceuticals, Inc. Common Stock (APLS) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets.Apellis Pharmaceuticals ( NASDAQ: APLS) announced Tuesday that the company will reduce approximately 25% of its workforce in Q3 as part of a corporate restructuring initiative aimed at saving up ...14 нояб. 2023 г. ... Is Apellis Pharmaceuticals (NASDAQ:APLS) a buy? Compare the latest price, visualised quantitative ratios, annual reports, ...May 31, 2023 · 9,367,396. 841,461. 11.1323. Back to APLS Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid ...

About Latest Pre-Market Trades. Nasdaq provides market information opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Nasdaq MarketSIte. Do Not Sell My Personal Information (CA ...Apellis Pharmaceuticals ( NASDAQ:APLS – Get Free Report) last issued its quarterly earnings results on Wednesday, November 1st. The company reported ($1.17) EPS for the quarter, missing analysts ...

The average twelve-month price prediction for Apellis Pharmaceuticals is $66.50 with a high price target of $93.00 and a low price target of $29.00. Learn more on APLS's analyst rating history. Do Wall Street analysts like Apellis Pharmaceuticals more than its competitors?

WALTHAM Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved ...20 de jul. de 2023 ... As of July 6, 2023, the average one-year price target for Apellis Pharmaceuticals is 104.04. The forecasts range from a low of 76.76 to a high ...value. Forecast 12 Month Forward PEG Ratio. -0.44. Investors are always looking for companies with good growth prospects selling at attractive prices. One popular statistic used to identify such ...Apellis pharmaceuticals, inc. (nasdaq:apls) saw its share price drive 177% higher over five years. Shareholders gained a total return of 0.7% in the last quarter. Apellis pharmaceuticals made a loss in the past year, but has seen revenue growth of 43% per year. The company has a good track record of growing its revenue at a compound rate of 23% ...Apellis Pharmaceuticals, Inc. (APLS) NasdaqGS - NasdaqGS Real Time Price. Currency in USD. Follow. 2W 10W 9M. 60.83 +6.96 (+12.92%) As of 02:29PM EST. Market open. 1d.

Nov 30, 2023 · For instance, the price of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stock is up an impressive 177% over the last five years. It's also good to see the share price up 19% over the last quarter.

WALTHAM Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company ...

Noteworthy Monday Option Activity: BILL, APLS, CVNA. October 09, 2023 — 03:23 pm EDT. Written by BNK Invest for BNK Invest ->. Looking at options trading activity among components of the Russell ...WALTHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company ...CRESTWOOD, Ky. and WALTHAM, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel ...WALTHAM, Mass. and CRESTWOOD, Ky., June 06, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel ...Apellis Pharmaceuticals, Inc.'s APLS newly marketed product, Syfovre (pegcetacoplan injection), was approved for the treatment of geographic atrophy (GA) secondary to age-related macular ... NASDAQ:APLS Long Term Investor Notice: Investigation of Potential Wrongdoing at Apellis Pharmaceuticals, Inc. An investigation on behalf of current long term investors in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) shares over possible breaches of fiduciary duty by certain officers and directors was announced.

The latest price target for . Apellis Pharmaceuticals (NASDAQ: APLS) was reported by Goldman Sachs on November 9, 2023.The analyst firm set a price target for $74.00 expecting APLS to rise to ... Apellis Pharmaceuticals, Inc. Common Stock (APLS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Since Friday, Apellis Pharmaceuticals Inc (NASDAQ:APLS) shares have plummeted around 50% after the stock came under pressure following the disclosure of safety events connected to Syfovre. Syfovre ...Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares are trading lower amid safety concerns regarding the company's newly launched Syfovre (pegcetacoplan injection) for geographic atrophy (GA ...Hedge funds poured into Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) in even greater numbers during Q2, as the number of funds long APLS rose by 27% to reach a new all-time high and propel it to ...Get the latest Apellis Pharmaceuticals Inc (APLS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced the closing ...

Find the latest Earnings Report Date for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.Wall Street Analysts Predict a 51.91% Upside in Apellis Pharmaceuticals, Inc. (APLS): Here's What You Should Know. (Zacks) Oct-25-23 07:00AM. Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results.

WALTHAM, Mass., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the U.S. Food and ...On today's stock market, APLS stock plummeted 37.9% to 52.46. ... *Real-time prices by Nasdaq Last Sale. Realtime quote and/or trade prices are not sourced from all markets.With a volume of 1,248,030, the price of APLS is up 1.39% at $51.0. RSI indicators hint that the underlying stock may be approaching overbought. Next earnings are expected to be released in 82 days.Nasdaq provides an interactive stock information chart to view history. Downloadable stock history data table is also accessible by clicking on Data Table on the navigation tool bar. If you have ...Find the latest Earnings Report Date for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.Stock Quote & Chart. NASDAQ: APLS. $61.58. Dec 1, 2023 4:00 PM EST. Change. +7.71 (+14.31%). Volume. 5,431,264. Today's Open. $53.99. Previous Close. $53.87.Apellis Pharmaceuticals Stock Up 14.3 %. APLS stock traded up $7.71 during midday trading on Friday, hitting $61.58. The company’s stock had a trading volume of 5,431,264 shares, compared to its ...Nov 24, 2023 · Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report)’s stock price traded down 3.7% on Wednesday after an insider sold shares in the company. The stock traded as low as $47.20 and last traded at $47.55. 370,506 shares changed hands during trading, a decline of 86% from the average session volume of 2,690,365 shares. The stock […]

Apellis Pharmaceuticals APLS WideScreen charts, DMA,SMA,EMA technical analysis, forecast prediction, by indicators ADX,MACD,RSI,CCI NASDAQ stock exchange.

Apellis Pharmaceuticals, Inc. Common Stock (APLS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Apellis Pharmaceuticals (NASDAQ: APLS ) shares plunged Monday on the back of a short report from Citron Research, which said the "happy days are over" for the company. The short-selling firm said it has "reason to believe that CEO Cedric Francois is not being honest with Wall St. about the report cases of vasculitis" regarding the …WALTHAM, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that it has ...WALTHAM Mass. and CRESTWOOD, Ky., March 06, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel ...We challenge conventional thinking and always question if there's a better way. Apellis is a global biopharmaceutical company that develops life-changing therapies. By pioneering targeted C3 therapies, we aim to treat diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology ...Operating as a commercial-stage biopharmaceutical entity, Apellis Pharmaceuticals (NASDAQ:APLS) is dedicated to the discovery, development, and market introduction of groundbreaking therapeutic ...Nov 17, 2023 · Apellis Pharmaceuticals Inc (NASDAQ:APLS) showed a performance of 4.00% in past 30-days. Number of shares sold short was 16.23 million shares which calculate 7.13 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $71.19 to the stock, which implies a rise of 32.73% to its current value. Aug 22, 2023 · WALTHAM, Mass., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) (“the Company”) today provided an update on injection kits supplied by Apellis and an update on ... Nov 29, 2023 · The public float for APLS is 96.80M and currently, short sellers hold a 16.67% of that float. On November 29, 2023, APLS’s average trading volume was 2.29M shares. APLS) stock’s latest price update. Apellis Pharmaceuticals Inc (NASDAQ: APLS)’s stock price has plunge by 5.56relation to previous closing price of 47.16. If you want to know who really controls Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), then you'll have to look at the makeup of its share registry. Large companies usually have institutions as ...WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...Apellis Pharmaceuticals Insider Sold Shares Worth $444,620, According to a Recent SEC Filing. Nov. 21. MT. Mizuho Raises Price Target on Apellis Pharmaceuticals to $49 …

WALTHAM, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to 20 new employees with a grant ...value. Forecast 12 Month Forward PEG Ratio. -0.44. Investors are always looking for companies with good growth prospects selling at attractive prices. One popular statistic used to identify such ...WALTHAM, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today provided an update on its New ...Instagram:https://instagram. employee engagement software marketcshioption trading platforms ustse acb stock price WALTHAM, Mass. and NANTES, France, June 22, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc (Nasdaq: APLS) and Affilogic today announced that the companies have expanded their research and development (R&D) collaboration, which was initially formed in 2018, to include the development of Nanofitins® targeting … aapl twitsweapon stocks Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin ... best ppo health insurance in florida How much insider selling is happening at Apellis Pharmaceuticals? Insiders have sold a total of 851,250 Apellis Pharmaceuticals shares in the last 24 months for a total of $50,097,256.67 sold.Apellis Pharmaceuticals (APLS). Common Shares. Sell: $47.51|Buy: $48.04|Change: 1.73 (-3.50%).Cash and cash equivalents of $765 million as of March 31, 2023; expected cash runway into Q1 2025. WALTHAM, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its first quarter 2023 financial results and business highlights.